Integra LifeSciences Expands OrthoBiologics Product Line

Integra Mozaik(TM) Osteoconductive Scaffold Now Available in a New Size for Expanded Surgical Applications

PLAINSBORO, N.J., Jul 13, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that Integra Mozaik(TM) Osteoconductive Scaffold strip is now available in a smaller configuration, broadening Integra's OrthoBiologics portfolio and providing surgeons with a wider selection of products that will satisfy their bone grafting needs.

Integra Mozaik(TM) Osteoconductive Scaffold is designed to fill bone voids or gaps in the skeletal system of the extremities, spine and pelvis. Integra Mozaik(TM) guides the regeneration of new bone across critical defect sites in which it has been implanted. New bone formation is initiated in the matrix surface when the graft is placed in direct apposition to living host bone. The matrix is resorbed and remodeled as new bone is formed. Integra Mozaik(TM) incorporates the same Type I collagen used in several of Integra's innovative regenerative products, including DuraGen(R) Plus Dural Regeneration Matrix, NeuraGen(R) Nerve Guide, and INTEGRA(R) Dermal Regeneration Template. Integra Mozaik(TM) combines the collagen matrix with a highly pure form of beta-tricalcium phosphate to provide both compression resistance and a mineral source, two properties essential for bone healing.

When used with bone marrow aspirate from the patient, Integra Mozaik(TM) Osteoconductive Scaffold may replace the need to harvest bone from the patient's iliac crest, thus sparing the patient additional surgery and postoperative pain.

"The addition of this new configuration reflects Integra OrthoBiologics' commitment to expand our orthobiologics portfolio and further Integra's mission to provide products that improve the quality of life," said Bill Weber, Vice President of Integra OrthoBiologics.

Degenerative disease of the spine may affect nearly all adults and is increasingly prevalent in the aging population. Patients who experience severe pain and do not respond to conservative therapies may require fusion of one or more vertebrae (spinal fusion). A spinal fusion is successful when the bones grow together biologically and form a solid mass. Bone grafts, or other materials that facilitate bone growth, are frequently used by surgeons to aid and promote bone growth to achieve this desired biological fusion.

The U.S. market size for bone graft substitutes in orthopedic spinal procedures is estimated at $1.4 billion. In 2008, an estimated 880,000 orthopedic procedures were performed in the United States, including over 500,000 spinal fusions. Additional applications are found in orthopedic trauma and reconstructive procedures.

Integra Mozaik(TM) Osteoconductive Scaffold is sold in the United States through the Integra OrthoBiologics distributor network, which currently distributes Accell(R), DynaGraft(R), and OrthoBlast(R) demineralized bone matrices, as well as the Integra Mozaik(TM) Osteoconductive Scaffold (Strip and Putty). This extensive product line allows the distributor network to provide a complete range of bone graft substitutes to orthopedic surgeons and neurosurgeons.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in neurosurgery, orthopedics and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.Integra-LS.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART - P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
Gianna Sabella, Director of Corporate Communications
(609) 936-2389
gsabella@Integra-LS.com